ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

TREATMENT OF IBS-D CASES THROUGH RIFAXIMIN

AUTHORS:

Dr. Saba Shabir, Dr. Qamar Gul, Dr. Jawariya Zia

ABSTRACT:

Objectives: Our aim was to observe the outcome of Rifaximin for the cases having IBS-D. Study design: A descriptive case control study. Place and Duration: We conducted this study for a time duration of 12 months starting from the month of January, 2018 to month of December, 2018 at medical OPD of Services Hospital in Lahore. Methodology: A total number of 30 patients matching the Rome II diagnostic criteria for IBS were selected for the study amongst which there were 12 males and 18 females. All selected patients were having age of more than 14 years. Linkert scoring system was used for selection of patients as according to this system only those patients were selected who rated the average daily amount of abdominal pain and bloating as a score of 2 or more than two. Mean makeup of stools typically per day is calculated through 5-point scale stool regularity. All those patients who were having colonic malignancy, kidney failure, chronic liver disease, human immune defect virus toxicity, hyper thyroids, hyper thyroids, high blood sugar, instigative bowel ailment and its descriptions, IBS major constipation, cases diagnosed through anti spasmodic, anti-psychotics, probiotics, anti-narcotics and probiotics or other antibiotic in last 14 days were not included in the study. Results: A total number of 30 cases were referred to the OPD for the analysis of IBS-D out of which 18 were females and 12 were males with the percentage of 60.0% and 40.0% respectively. Cases have 13-38 years of age. All the cases were suggested to use Tablet Rifaximin 550 mg in a rotation of three within 24 hours for a period of two weeks and directed to use the Li Kert scale and 5-point scale for the regularity and frequency level of diarrhea and its treatment for the abdominal pain, bloating and stool constancy. Cases were evaluated to consult again for the checkup after two weeks on the on the 15th day and after 60 days again. As an observation of 30 diagnosed cases out of which 18 cases with the percentage of 60.0% got relief in their IBS-D ailment during the treatment within two weeks but only 12 cases with the percentage of 40.0% out of 18 cases with the percentage of 60.0% which reacted to the diagnosis through Rifaximin in a duration of 60 days were found regular cured from the indication of this disease whereas 6 cases with the percentage of 20.0% still have progressed IBS-D. Because of setup in level of diarrhea, 2 cases with the percentage of 6.0% left the treatment on the 3rd day of diagnosis. Females were 11 with the percentage of 61% from the 18 reacted cases and were older in age comparatively. Details are shown in the below table. Conclusion: According to the results of our study, Rifaximin was observed to deliver most liberation in the indications and treatment of IBS-D Key Words: Diarrhea, Irritable bowel syndrome IBS and Rifaximin.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.